Article (Scientific journals)
In-Depth Assessment of Endoscopic Remission in Inflammatory Bowel Disease Treated by Anti-TNF or Vedolizumab.
Loly, Jean-Philippe; Vieujean, Sophie; Reenaers, Catherine et al.
2023In Inflammatory Bowel Diseases
Peer Reviewed verified by ORBi
 

Files


Full Text
Cellvizio.pdf
Publisher postprint (259.38 kB)
Request a copy

All documents in ORBi are protected by a user license.

Send to



Details



Keywords :
confocal endomicroscopy; inflammatory bowel disease; mucosal healing
Abstract :
[en] BACKGROUND AND AIMS: Confocal endomicroscopy is a technique allowing the in vivo assessment of the superficial layers of the mucosa. Preliminary studies have already suggested its added value in the assessment of endoscopic remission in inflammatory bowel disease. However, most of these studies were performed on patients still having incomplete mucosal healing. Our aim was to disclose persisting endomicroscopic anomalies in patients with full endoscopic remission and to compare them between vedolizumab- and anti-tumor necrosis factor-treated patients. METHODS: We screened patients with Crohn's disease (CD) or ulcerative colitis (UC) treated for more than 6 months with biologic therapy, and being in steroid-free clinical and biological remission. White light endoscopy and probe-based confocal laser endomicroscopy (pCLE) analysis were performed in the ileum, right colon, transverse colon, left colon, and rectum. Full endoscopic remission was defined by a Mayo endoscopic score of 0 in UC and no remaining ulcer or erosion in CD. Patients were prospectively followed up and clinical relapses were recorded. RESULTS: Seventy-two CD and UC patients treated by biologic therapy and in clinical and biological remission were screened. A total of 37 were also in full endoscopic remission and were included in our study; 183 intestinal segments were analyzed. We found residual pCLE anomalies in most of the patients. These anomalies were not significantly associated with any demographic or clinical characteristic including the treatment received, nor were they associated with histological parameters, levels of C-reactive protein or fecal calprotectin. Among the 37 patients, 7 (18.9%) relapsed over a median follow-up of 33.7 months. The risk of relapse was not associated with any clinical, biological, histologic, or pCLE feature at baseline. CONCLUSION: Despite endoscopic, biological, and even histological remission, we found a high prevalence of endomicroscopic abnormalities, which were not different between anti-tumor necrosis factor- and vedolizumab-treated patients. The clinical significance of these anomalies remains to be clarified.
[en] We studied the abnormalities found by confocal endomicroscopy in patients with chronic inflammatory disease in deep endoscopic remission under immunosuppressive treatment. Relapse was not associated with the abnormalities found, which, although numerous, remain of unknown significance.
Disciplines :
Gastroenterology & hepatology
Author, co-author :
Loly, Jean-Philippe  ;  Centre Hospitalier Universitaire de Liège - CHU > > Service de gastroentérologie, hépatologie, onco. digestive
Vieujean, Sophie  ;  Centre Hospitalier Universitaire de Liège - CHU > > Service de gastroentérologie, hépatologie, onco. digestive
Reenaers, Catherine ;  Centre Hospitalier Universitaire de Liège - CHU > > Service de gastroentérologie, hépatologie, onco. digestive
Van Kemseke, Catherine ;  Centre Hospitalier Universitaire de Liège - CHU > > Service de gastroentérologie, hépatologie, onco. digestive
Seidel, Laurence  ;  Centre Hospitalier Universitaire de Liège - CHU > > Service des informations médico économiques (SIME)
Louis, Edouard  ;  Centre Hospitalier Universitaire de Liège - CHU > > Service de gastroentérologie, hépatologie, onco. digestive
Somja, Joan ;  Centre Hospitalier Universitaire de Liège - CHU > > Service d'anatomie et cytologie pathologiques
Language :
English
Title :
In-Depth Assessment of Endoscopic Remission in Inflammatory Bowel Disease Treated by Anti-TNF or Vedolizumab.
Publication date :
12 April 2023
Journal title :
Inflammatory Bowel Diseases
ISSN :
1078-0998
eISSN :
1536-4844
Publisher :
Oxford University Press (OUP), England
Peer reviewed :
Peer Reviewed verified by ORBi
Available on ORBi :
since 04 May 2023

Statistics


Number of views
85 (11 by ULiège)
Number of downloads
0 (0 by ULiège)

Scopus citations®
 
2
Scopus citations®
without self-citations
2
OpenCitations
 
0

Bibliography


Similar publications



Contact ORBi